NSMP versus p53-mutated endometrial carcinomas; a retrospective data analysis of the patient records from the Department of Gynecology and Gynecologic Oncology at the University Hospital Bonn (2020–2025) with regard to the tumor stage at initial diagnosis, as well as the occurrence of the symptom of postmenopausal/atypical bleeding.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00039692

Enrollment

279

Registered

2026-04-13

Start date

2026-04-13

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C54.1

Interventions

Group 1: This is a retrospective data analysis of patient data generated in routine clinical practice from patients who were treated between 2020 and 2025 at the Department of Gynecology and Gynecolog

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosed with endometrial cancer

Exclusion criteria

Exclusion criteria: Patients with diagnosed Carcinosarcoma

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the investigation of the tumor stage and symptoms—particularly postmenopausal/atypical bleeding—at the time of initial diagnosis in patients with endometrial carcinoma, depending on the respective molecular subtype. The data were generated in routine clinical practice and are already fully available prior to the start of the analysis.	—

Secondary

Measure	Time frame
Currently, there is no defined secondary endpoint. This may change depending on the available data, and will of course be adjusted accordingly if necessary.	—

Countries

Germany

Contacts

Public ContactLucia Otten

Klinik für Gynäkologie und gynäkologische Onkologie

gynaekologie@ukbonn.de+49 228 287 - 15450

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026